Imagene is a pioneering company in AI-based precision oncology, dedicated to decoding cancer using biopsy images. Our mission is to unlock the power of Oncology Intelligence to transform cancer research and diagnostics.
Imagene’s OI Suite platform leverages our state-of-the-art vision foundation model to provide fast, user-friendly, and data-efficient AI to advance drugs into the clinic. LungOI, our first application, is an AI-based NSCLC multi-gene test that offers rapid biomarker profiling, facilitating informed clinical decisions.
Imagene has been awarded the Digital Health Award for “Best Use of AI in HealthTech” and the Technology Leadership Best Practices Award by Frost & Sullivan and is committed to advancing precision oncology and enhancing care for cancer patients worldwide.
